Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-52 (canceled)

53 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal an effective amount of a compound of the formula (I):



(I)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_1 is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

$-R_4-$ heteroaryl; and

$-R_4-$heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-$CO\text{-}N(R_3)_2$;

-$CO\text{-}C_{1\text{-}10}$ alkyl;

-$CO\text{-}O\text{-}C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

$\mathbf{R_4}$ is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each $\mathbf{R_3}$ is independently H or $C_{1\text{-}10}$ alkyl;

each **Y** is independently –O– or $-S(O)_{0\text{-}2}$-;

n is 0 to 4; and

each **R** present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

54. (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal an effective amount of a compound of the formula (II):



(II)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

$\mathbf{R_{10}}$ is selected from the group consisting of heteroaryl and heterocyclyl;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

$-CO-O-C_{1-10}$ alkyl;

$-N_3$;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

n is 0 to 4;

each $\mathbf{R_3}$ is independently H or $C_{1\text{-}10}$ alkyl;

each **Y** is independently –O– or $–S(O)_{0\text{-}2}–$; and

each **R** present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

55. (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal an effective amount of a compound selected from the group consisting of:

1-(2-{[3-(isoquinolin-4-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-{[3-(1,3-thiazol-2-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[3-(1*H*-4-pyrazolyl)propoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyrimidin-2-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyridin-4-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyridin-2-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[3-(1,3-thiazol-2-yl)propoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-pyrimidin-5-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(1-benzyl-1*H*-1,2,3-triazol-4-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-{2-[(1-benzyl-1*H*-1,2,3-triazol-5-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-({1-[(phenylsulfanyl)methyl]-1*H*-1,2,3-triazol-4-yl}methoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-({1-[(phenylsulfanyl)methyl]-1*H*-1,2,3-triazol-5-yl}methoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-(benzo[b]furan-2-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(pyridin-3-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(pyridin-2-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(pyridin-4-ylmethoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(3,5-dimethylisoxazol-4-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-{[3-(pyrimidin-2-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-{[3-(pyrid-4-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-{[3-(fur-3-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

4-{3-[2-(4-amino-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]-propyn-1-yl}
thiophen-2-ylcarboxaldehyde;

1-(2-{[3-(pyrid-2-yl)-2-propynyl]oxy}ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-methyl-1-[(pyrid-2-yloxy)methyl]propyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-{1-[(pyrid-2-yloxy)methyl]propyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-(9*H*-carbazol-3-yloxy)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(3-thien-2-ylprop-2-ynyl)oxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(1-methyl-1*H*-indol-2-yl)methoxy]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(3-thien-2-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-methyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

2-butyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

1-[2-(tetrahydrofuran-2-ylmethoxy)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(5-chloro-1-benzothien-3-yl)methoxy]propyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-{2-[(3-nitropyridin-2-yl)oxy]propyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(2-methyl-1-{[(3-nitropyridin-2-yl)oxy]methyl}propyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-(1-{[(5-chloro-1-benzothien-3-yl)methoxy]methyl}-2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-(2-methoxyethyl)-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and

2-methyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

or a pharmaceutically acceptable salt thereof.

56. (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal an effective amount of a compound of the formula (III):



(III)

wherein: **X** is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_1 is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R_4– heteroaryl; and

-R_4–heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

$\mathbf{R_4}$ is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each $\mathbf{R_3}$ is independently H or C_{1-10} alkyl;

each **Y** is independently –O– or $-S(O)_{0-2}$-;

n is 0 to 4; and

each **R** present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

57. (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal an effective amount of a compound of the formula (IV):



(IV)

wherein: **X** is –CHR_3-, -CHR_3-alkyl-, or –CHR_3-alkenyl-;

$\mathbf{R_{10}}$ is selected from the group consisting of heteroaryl and heterocyclyl;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

$-CO-O-C_{1-10}$ alkyl;

$-N_3$;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each $\mathbf{R_3}$ is independently H or C_{1-10} alkyl;

each **Y** is independently –O– or $-S(O)_{0-2}-$;

n is 0 to 4; and

each **R** present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.